
Affinity Biosensors is dedicated to transforming antibiotic susceptibility testing with its Life Scale system, which utilizes patented population profiling and advanced AI technology to deliver the fastest and most accurate rapid antimicrobial susceptibility testing (AST) results. The Life Scale system addresses the critical need for timely diagnostics in the face of rising antimicrobial resistance, providing results in just 4.5 hours, significantly faster than traditional methods. This innovative approach not only enhances patient care by enabling quicker treatment decisions but also supports antimicrobial stewardship by reducing unnecessary antibiotic use. With FDA clearance and proven reliability in clinical settings, Affinity Biosensors positions itself as a leader in the diagnostics market, catering to hospitals and laboratories seeking efficient and effective solutions for critical-care diagnostics.

Affinity Biosensors is dedicated to transforming antibiotic susceptibility testing with its Life Scale system, which utilizes patented population profiling and advanced AI technology to deliver the fastest and most accurate rapid antimicrobial susceptibility testing (AST) results. The Life Scale system addresses the critical need for timely diagnostics in the face of rising antimicrobial resistance, providing results in just 4.5 hours, significantly faster than traditional methods. This innovative approach not only enhances patient care by enabling quicker treatment decisions but also supports antimicrobial stewardship by reducing unnecessary antibiotic use. With FDA clearance and proven reliability in clinical settings, Affinity Biosensors positions itself as a leader in the diagnostics market, catering to hospitals and laboratories seeking efficient and effective solutions for critical-care diagnostics.
Flagship product: LifeScale rapid phenotypic antimicrobial susceptibility testing (AST) system — FDA-cleared
Time-to-result: Direct-from-positive blood culture results in as little as ~4.5–5 hours
Core technology: Patented population profiling using microfluidic mass sensing of individual bacteria + AI Predictor
Headquarters & founding: Santa Barbara, CA; founded 2006
Funding signals: Total funding reported ~27.9M USD; an Early VC round reported at $15.0M (Dec 2024)
Rapid antimicrobial susceptibility testing for bacteremia/sepsis diagnostics and antibiotic stewardship
2006
Biotechnology
$15.0M